Trial Scorecards

BIOFLOW V

Comparison of the safety and efficacy of a sirolimus-eluting stent (Orsiro, Biotronik) with an everolimus-eluting stent (Xience, Abbott Vascular) in patients with up to three native de novo or restenotic coronary artery lesions.

Comparison of the safety and efficacy of a sirolimus-eluting stent (Orsiro, Biotronik) with an everolimus-eluting stent (Xience, Abbott Vascular) in patients with up to three native de novo or restenotic coronary artery lesions.